Compare DexCom, Inc. (DXCM) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Futu Holdings Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Futu Holdings Ltd trades at $105.6 (market cap $14.74B). The key difference: DexCom, Inc. is far larger — about 2.3× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | FUTU | |
|---|---|---|
Market Cap | $33.79B | $14.74B |
Sector | Health | Financials |
52-Week High | $89.53 | $199.04 |
52-Week Low | $54.84 | $89.76 |
Enterprise Value | $33.24B | $14.59B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.
The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
